Details
Stereochemistry | ACHIRAL |
Molecular Formula | 3C6H4NO2.Cr |
Molecular Weight | 418.3005 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cr+3].[O-]C(=O)C1=CC=CC=N1.[O-]C(=O)C2=CC=CC=N2.[O-]C(=O)C3=CC=CC=N3
InChI
InChIKey=CBDQOLKNTOMMTL-UHFFFAOYSA-K
InChI=1S/3C6H5NO2.Cr/c3*8-6(9)5-3-1-2-4-7-5;/h3*1-4H,(H,8,9);/q;;;+3/p-3
Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0004714 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15924436 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | CHROMIUM Approved UseChromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. Launch Date2005 |
PubMed
Title | Date | PubMed |
---|---|---|
Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity. | 1996 Mar |
|
Activation of MAPKs in human bronchial epithelial cells exposed to metals. | 1998 Sep |
|
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate. | 1999 Dec |
|
The role of oxidative stress in the modulation of aryl hydrocarbon receptor-regulated genes by As3+, Cd2+, and Cr6+. | 2005 Dec 1 |
|
Transcriptional activation and posttranscriptional modification of Cyp1a1 by arsenite, cadmium, and chromium. | 2007 Aug |
|
Effects of subchronic exposure via drinking water to a mixture of eight water-contaminating metals: a biochemical and histopathological study in male rats. | 2007 Nov |
|
Immunosuppressive effect of subchronic exposure to a mixture of eight heavy metals, found as groundwater contaminants in different areas of India, through drinking water in male rats. | 2007 Oct |
|
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment. | 2017 Sep 21 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
41 (Number of products:6537)
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
||
|
FDA ORPHAN DRUG |
456814
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
||
|
DSLD |
2491 (Number of products:132)
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
S71T8B8Z6P
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
1133638
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
14639-25-9
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
C28931
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
50369
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
SUB127351
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
DB11255
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
SUB13363MIG
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
m3510
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000090351
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
4511
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
15713-60-7
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
ALTERNATIVE | |||
|
S71T8B8Z6P
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
Chromium(III) picolinate
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
151932
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
DTXSID1024831
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | |||
|
C1505
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
CONCEPT | Dietary Supplement | ||
|
59308
Created by
admin on Mon Mar 31 18:06:33 GMT 2025 , Edited by admin on Mon Mar 31 18:06:33 GMT 2025
|
PRIMARY | RxNorm |
ACTIVE MOIETY
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD